Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events

Abstract

Background and aims: Currently there is limited knowledge on medical comorbidities and COVID-19; we conducted a systematic review and meta-analysis to evaluate the impact of various morbidities on serious events in COVID 19. Methods: PubMed, Cochrane Central Register of Clinical Trials were searched on April 28, 2020, to extract published articles that reported the outcomes of COVID-19 patients. The search terms were "coronavirus" and "clinical characteristics". ICU admission, mechanical ventilation, ARDS, Pneumonia, death was considered serious events. The comorbidities assessed in the study were Hypertension (HTN), Diabetes mellitus (DM), Cardiovascular diseases (CVD), Chronic obstructive pulmonary disease (COPD) and Chronic Kidney disease (CKD). Subsequently, comparisons between comorbidity patient group and the non-comorbidity patient groups, in terms of serious events were made using the pooled estimates of odd's ratio (OR) Results: We identified 688 published results and 16 studies with 3994 patients were included in the systematic review. Serious events were seen in 526(13.16%) patients. Presence of hypertension with OR 2.95, diabetes mellitus with OR 3.07, Cardio vascular disease with OR 4.58, COPD with OR 6.66 and Chronic kidney disease with OR 5.32 had significant association in patients with COVID 19 on having serious events. Presence of diabetes mellitus (OR 2.78)) had a significant impact on death in COVID 19 patients with a p-value 0.004. Conclusions: Presence of medical comorbidities in COVID-19 leads to higher risk of developing serious events i.e. ICU admission, mechanical intubation and mortality. The presence of Diabetes mellitus has a significant impact on mortality rate in COVID-19 patients.

No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials”

“…At present, the mainstay of the clinical management of severely ill COVID-19 patients involves intensive monitoring of the clinical status with systemic support. The mortality rate in COVID-19 is observed to be highest among the elderly patients which might be due to the age-related immune dysfunction complicated with the associated comorbidities [ [4] , [5] , [6] ]. With no effective drug available against the SARS-CoV-2 infection, the focus is on identifying existing drugs that may be effective against the virus [ 7 , 8 ].…”

A Comparison of COVID-19 Epidemiology, Pathophysiology, and Impact on Vulnerable Populations in Two States within the USA

“…111 Recent studies have suggested that chronic obstructive pulmonary disease (COPD) is a major risk factor for COVID-19. 113,114 Adults with COPD exhibit upregulated ACE2 and TMPRSS2 in lung airways; asthmatic adults show slight upregulation of these genes as well. 110 An association between COVID-19 and COPD exacerbation has been noted.…”

A proposed ABCD scoring system for better triage of patients with COVID-19: Use of clinical features and radiopathological findings

“…and Salunke et al. had described higher morbidity and mortality rate inflicted by COVID-19 among patient with medical comorbidity including cancer [ 1 , 2 ]. Currently only symptomatic treatment and intensive care have been used for seriously ill patients.…”